| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/17/2003 | US20030134003 For reduction of bone marrow suppression side effect (leukopenia) |
| 07/17/2003 | US20030134000 Comprising aliquot of the herb Herba Epimedii and aliquot of three supplemental herbs selected from Fructus Rosae Laevigatae, Fructus Rubi, Fructus Psoralea, Radix Morindae Officinalis, Fructus Schisandrac Chinensis, and others |
| 07/17/2003 | US20030133998 Comprising diphenhydramine HCl, belladonna tincture, buffer, flavourants, absolute alcohol, wherein alcohol concentrate comprises 2.8%-3.2% by volume |
| 07/17/2003 | US20030133995 Neutralizing amount of casein protein, or salt thereof, alkali earth metal halide, water; to neutralize effect of capsaicin on oral cavity, tongue, and esophagus |
| 07/17/2003 | US20030133992 Method and composition for preventing or reducing the symptoms of insulin resistance syndrome |
| 07/17/2003 | US20030133991 Composition containing zinc ions, calcium ions, rubidium ions and/or potassium ions in carrier, which, when applied to open wound, modulates activity of MMP-2 and/or MMP- 9 in wound; ulcer treatment |
| 07/17/2003 | US20030133988 Immunomodulation accomplished by administration of immunomodulatory polynucleotide/microcarrier complexes comprising 3-6 mer immunomodulatory oligonucleotides |
| 07/17/2003 | US20030133986 Compositions for stabilizing poly (carboxylic acids) |
| 07/17/2003 | US20030133985 Controlled release oral dosage forms; data obtained using disintegration test such as the established USP Disintegration Test, rather than the results obtained using a standard USP Dissolution Test, as is conventionally done |
| 07/17/2003 | US20030133983 Comprises core and enteric coating, the core including, as a pharmaceutical active compound, aminosalicylic acid or a derivative thereof; treatment of ulcerative colitis and Crohn's disease |
| 07/17/2003 | US20030133982 Suitable for administration of a wide range of therapeutically active medicaments, especially those that are water-soluble; ethylcellulose core, active agent, hydrophobic polymer coating |
| 07/17/2003 | US20030133981 Extended release formulations of erythromycin derivatives |
| 07/17/2003 | US20030133977 Method of systemically delivering SSRIs |
| 07/17/2003 | US20030133974 Gelatin-encapsulated sertraline and a water immiscible vehicle shorten Tmax and/or reduce side effects and/or decrease sertraline precipitation in chloride ion-containing environments |
| 07/17/2003 | US20030133973 Vesicle-forming lipid and a vesicle-forming lipid derivatized with a hydrophilic polymer |
| 07/17/2003 | US20030133969 Topical agent capable of disrupting membrane or protein conformation in a target cell, tissue or microbe; does not contain nonoxynol-9, benzalkonium chloride or menfegol |
| 07/17/2003 | US20030133965 Application of phytosterols (and their isomers), folic acid, cyanocobalamin and pyridoxin in dietetic (alimentary) fibers |
| 07/17/2003 | US20030133959 Sulfur containing dermatological compositions and methods for reducing malodors in dermatological compositions |
| 07/17/2003 | US20030133954 Medical compositions for intravesical treatment of bladder cancer |
| 07/17/2003 | US20030133953 Complexing a biologically active agent with a perturbant to reversibly transform and exposing a membrane or bilayer to the supramolecular complex |
| 07/17/2003 | US20030133951 Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines |
| 07/17/2003 | US20030133945 Food supplement consists of apigenin a flavonoid in fruits and vegetables, crysin , colorius versicolor an edible mushroom, 3,3-diinolmethane, resveratol in grapes, tumeric, green tea extract, quercitin and selinium methionine |
| 07/17/2003 | US20030133940 Medicaments for chemotherapeutic treatment of disease |
| 07/17/2003 | US20030133932 Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents |
| 07/17/2003 | US20030133930 Administering to a patient having an autoimmune disorder an antibody to a B-cell antigens and a carrier; CD22, CD20, CD19, and CD74 or HLA-DR antigen. |
| 07/17/2003 | US20030133925 Monobactam compositions and methods of use thereof |
| 07/17/2003 | US20030133920 Koji molds for preparing cholesterol lowering products |
| 07/17/2003 | US20030133910 Inhibiting cell proliferation by administering a large dosage of wild-type ras proteins |
| 07/17/2003 | US20030133908 Treatment for intracranial tumors |
| 07/17/2003 | US20030133905 Composition for treating contact lenses in the eye |
| 07/17/2003 | US20030133903 Compositions for treatment of prostate cancers and methods of making and using the same |
| 07/17/2003 | US20030133902 Method of making phosphate-binding polymers for oral administration |
| 07/17/2003 | US20030133897 Long-lasting styling mousse |
| 07/17/2003 | US20030133893 Compositions and methods for treating skin ailments |
| 07/17/2003 | US20030133889 Treating skin and/or mucous membrane by applying an aqueous solution of ascorbic acid or a derivative stabilized by the polymer; oxidation resistance; sunscreen agents; combatting pollution, sunburn; free radical scavengers; skin tone |
| 07/17/2003 | US20030133888 Anticarcinogeninic and sunscreen agent containing ultraviolet radidation-A and -B absorbers and a derivative of delta-aminolevulinic acid, e.g., the methyl ester; non toxic; side effects reduction |
| 07/17/2003 | US20030133880 Powdery pharmaceutical compositions for inhalation |
| 07/17/2003 | US20030133877 For inhibiting a cerebral neurovascular disorder, a muscular headache, or cerebral inflammation; administering to patient using intranasal drug delivery device |
| 07/17/2003 | US20030133875 Assay for screening candidate drug for the treatment of inflammatory diseases and methods for treating the same |
| 07/17/2003 | US20030133839 Method and apparatus for reducing static charges during polymerization of olefin polymers |
| 07/17/2003 | US20030132028 Arrangement for the removal of cuttings and gas arising from drilling operations |
| 07/17/2003 | DE20305138U1 Medicament, useful for the treatment of amyotrophic lateral sclerosis and for improving motor activity, comprises a melatonin compound |
| 07/17/2003 | CA2825792A1 Otoprotectant compositions of glutathione peroxidase mimics for ameliorating hearing loss |
| 07/17/2003 | CA2767061A1 Specific binding agents of human angiopoietin-2 |
| 07/17/2003 | CA2473106A1 Pravastatin pharmaceutical formulations and methods of their use |
| 07/17/2003 | CA2473081A1 Use of phospholipids in peritoneal dialysis |
| 07/17/2003 | CA2473043A1 Pharmaceutical composition comprising a glitazone and a 4-oxobutanoic acid, and the use thereof for treating diabetes |
| 07/17/2003 | CA2472893A1 Cancer treatment |
| 07/17/2003 | CA2472678A1 Otoprotectant compositions of glutathione peroxidase mimics for ameliorating hearing loss |
| 07/17/2003 | CA2472633A1 S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer |
| 07/17/2003 | CA2472617A1 Substituted amino carboxamides for the treatment of alzheimer's disease |
| 07/17/2003 | CA2472585A1 Drug mixture with enhanced dissolution rate |
| 07/17/2003 | CA2472583A1 Porphyrins with virucidal activity |
| 07/17/2003 | CA2472580A1 Broad spectrum inhibitors |
| 07/17/2003 | CA2472331A1 Process and intermediates for pyridazinone antidiabetic agents |
| 07/17/2003 | CA2472282A1 Gene products differentially expressed in cancerous breast cells and their methods of use |
| 07/17/2003 | CA2472198A1 Drug delivery systems for the prevention and treatment of vascular diseases comprising rapamycin and derivatives thereof |
| 07/17/2003 | CA2472165A1 3,4-di-substituted pyridazinediones as cxc chemokine receptor antagonists |
| 07/17/2003 | CA2472151A1 Combination treatments for allergic disease comprising administering an anti-ige antibody and antiallergic compound |
| 07/17/2003 | CA2472118A1 Pak5-related compositions and methods |
| 07/17/2003 | CA2472111A1 Human mast cell-expressed membrane proteins |
| 07/17/2003 | CA2471994A1 Hemostatic compositions and methods for controlling bleeding |
| 07/17/2003 | CA2471953A1 Hydroxamic acid and its derivatives as inhibitors of melanocyte tyrosinase for topical skin lighteners |
| 07/17/2003 | CA2471951A1 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin |
| 07/17/2003 | CA2471932A1 A nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer |
| 07/17/2003 | CA2471885A1 4-sulfide / sulfoxide / sulfonyl-1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor |
| 07/17/2003 | CA2471880A1 1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor |
| 07/17/2003 | CA2471874A1 Compositions and methods for hydroxylating epothilones |
| 07/17/2003 | CA2471846A1 Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor |
| 07/17/2003 | CA2471760A1 Preventives/remedies for urinary disturbance |
| 07/17/2003 | CA2471754A1 Androgen receptor antagonist |
| 07/17/2003 | CA2471752A1 Carboxamidine derivatives and their use in the treatment of vascular diseases |
| 07/17/2003 | CA2471750A1 Polyphenol inhibition of nucleoside diphosphate kinase-b activity and cancer metastasis |
| 07/17/2003 | CA2471715A1 A stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof |
| 07/17/2003 | CA2471657A1 Methods for improving the aesthetic appearance of skin |
| 07/17/2003 | CA2471572A1 Taxane based compositions and methods of use |
| 07/17/2003 | CA2471566A1 Combination of mtp inhibitors or apob-secretion inhibitors with fibrates for use as pharmaceuticals |
| 07/17/2003 | CA2471509A1 Combinations comprising epothilones and anti-metabolites |
| 07/17/2003 | CA2471504A1 Ligand for g-protein coupled receptor gpr43 and uses thereof |
| 07/17/2003 | CA2471432A1 Nonhuman model animal lacking the ability to control lymphocyte migration |
| 07/17/2003 | CA2471211A1 Drug delivery system for sustained delivery of glipizide |
| 07/17/2003 | CA2471204A1 Inhibitors of dipeptidyl peptidase iv |
| 07/17/2003 | CA2470496A1 A stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof |
| 07/17/2003 | CA2470495A1 Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it |
| 07/17/2003 | CA2470411A1 System for monitoring bacterial tumor treatment |
| 07/17/2003 | CA2470164A1 New crystalline forms of meloxicam and processes for their preparation and interconversion. |
| 07/17/2003 | CA2469162A1 Composition inhibiting matrix-metallproteinases for the treatmentof neoplastic diseases |
| 07/17/2003 | CA2463798A1 Modulation of immunostimulatory propertiies of oligonucleotide-based compounds by optimal presentation of 5' ends |
| 07/17/2003 | CA2460343A1 Delivery of caffeine through an inhalation route |
| 07/17/2003 | CA2368285A1 Therapy |
| 07/16/2003 | EP1327887A2 Use of thiazolium compounds for preventing and reversing the formation of advanced glycosylation end products |
| 07/16/2003 | EP1327683A2 Human papilloma virus inhibition by a hairpin ribozyme |
| 07/16/2003 | EP1327630A1 New derivatives of cyano-aryl (or cyanoheteroaryl)-carbonyl-piperazinyl-pyrimidines, their preparation and application as medication |
| 07/16/2003 | EP1327628A2 Lipidization of hydrophilic molecules |
| 07/16/2003 | EP1327627A1 Compounds and method for preparing substituted 4-phenyl-4-cyanocyclohexanoic acids |
| 07/16/2003 | EP1327463A1 Gel comprising Cetirizine and Loratadine for topical application |
| 07/16/2003 | EP1327453A1 Stable taurolidine electrolyte solutions |
| 07/16/2003 | EP1327452A2 Pharmaceutical compositions based on anticholinergically effective compounds and beta-mimetics |
| 07/16/2003 | EP1327449A1 Remedies for ischemic diseases |
| 07/16/2003 | EP1327448A1 Homeostasis-maintaining agents |